Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(59)

カスタマーフィードバック(10)

Quality Control & MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
M07ep210 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp NEHaVGtFVVOR MnjsTWM2OD1yLkCwNFA4KM7:TR?=
K562 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxO|IhcA>? NVO3OplyTE2VTx?= MlW0TWM2OD1yLkCwNUDPxE1?
M07e NYrt[WRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp NH3ReZdFVVOR MofmTWM2OD1yLkCwNVIh|ryP
ALL3 NFzhU3pEgXSxdH;4bYMhSXO|YYm= MUiwMlHPxE1? NXfMSmpIPzJiaB?= MXXEUXNQ NWPWcHdPUUN3ME2wMlAxODRizszN
CML NXy5V5BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13zVVIxKG2rbh?= MnjySG1UVw>? NYfobZBYUUN3ME2wMlAxOSEQvF2=
BA/F3 NV;pb|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly0O|IhcA>? NVK1PVhFTE2VTx?= NVnwWpBkUUN3ME22MlU5QSEQvF2=
BA/F3 NXvufIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TzWFczKGh? NIrScVVFVVOR MWHJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=
BA/F3 NV3pVYE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP0Vm04OiCq MVXEUXNQ NXPvb2F2UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?=
BA/F3 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJUZA4OiCq NH73V3FFVVOR NELhcnVKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=
BA/F3 M1fUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfaemw4OiCq NYHxU21RTE2VTx?= NF3mZ2tKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?=
BA/F3 M2rqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGzPVA4OiCq MX3EUXNQ NX;Ie4RpUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2=
BA/F3 M3SyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrUlczKGh? NETZZoVFVVOR MYfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>?
BA/F3 M1znNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPJVXNqPzJiaB?= M1fFdWROW09? M1e1ZWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1?
BA/F3 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW3NkBp NE\PdpRFVVOR Mnn4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?
BA/F3 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VNFY4OiCq M{fkNWROW09? NGS5PZZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>?
BA/F3 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mzUlczKGh? NYnqVVk{TE2VTx?= NUfwVVl{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=
BA/F3 NGe4WmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjmcVFSPzJiaB?= MkfCSG1UVw>? MmTkTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0>
BA/F3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\z[3c4OiCq NGjaSW5FVVOR M4HsN2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?=
T cell MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NkBp NUnrSYdpTE2VTx?= MojDTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>
WiDr M2XwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn3U2g4OiCq M1P0SmROW09? NImwN|BKSzVyPUCuNFUzKM7:TR?=
PC3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWwO|IhcA>? Mk\JSG1UVw>? M1TKZWlEPTB;MD6wNFk1KM7:TR?=
MDA-MB-231 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHkRZc4OiCq NXnyb|Z3TE2VTx?= M2[5fmlEPTB;MD6wNVIh|ryP
Hs578T NWjJcoNIS3m2b4TvfIlkKEG|c3H5 NEHZ[og4OiCq NV3oXHE4TE2VTx?= M3rsN2dKPTB;MD6wN{DPxE1?
HMEC NEe1cJlEgXSxdH;4bYMhSXO|YYm= MYq3NkBp NI\iXWhFVVOR MUPHTVUxRTFwODFOwG0>
DU145 Mo\uR5l1d3SxeHnjJGF{e2G7 NVfyXHcyPzJiaB?= M3jNOWROW09? MorjS2k2OD1yLkG2JO69VQ>?
U251 NWn0Wo9QS3m2b4TvfIlkKEG|c3H5 NVfCVWR6PzJiaB?= Ml7ESG1UVw>? NUfaNZBrT0l3ME2yMlgyKM7:TR?=
NCI60 NEPvOodEgXSxdH;4bYMhSXO|YYm= M1TpeFczKGh? NWLNbpVUTE2VTx?= MW\HTVUxRTVwNzFOwG0>
MALME-3M Mn:wR5l1d3SxeHnjJGF{e2G7 MVS3NkBp NVXJdJlTTE2VTx?= M2izemdKPTB;Nj62NUDPxE1?
KM12 MUfDfZRwfG:6aXOgRZN{[Xl? NF6ye3U4OiCq M{Dz[mROW09? NVHLd5pCT0l3ME23MlQ1KM7:TR?=
SW620 MVjDfZRwfG:6aXOgRZN{[Xl? NXOyeJBNPzJiaB?= NWXqUoNbTE2VTx?= MUHHTVUxRThwNEOg{txO
RXF 393NL NEHCfnBEgXSxdH;4bYMhSXO|YYm= NXz3PVBoPCCmYYnz MVjEUXNQ Mo[4TWM2OD1yLkCyNVch|ryP
LXFA 983L MojXR5l1d3SxeHnjJGF{e2G7 NWn3XIN3PCCmYYnz NEj1dWFFVVOR NFfKO2pKSzVyPUCuNFU3PSEQvF2=
PRXF DU145 M1HGeGN6fG:2b4jpZ{BCe3OjeR?= NHvaeGs1KGSjeYO= MlHWSG1UVw>? MXfJR|UxRTBwME[yN{DPxE1?
PAXF 1657L M37aV2N6fG:2b4jpZ{BCe3OjeR?= NV;iR|BxPCCmYYnz MXPEUXNQ NFTDc2tKSzVyPUCuNVIyKM7:TR?=
CXF 1103L Mm\FR5l1d3SxeHnjJGF{e2G7 NHjsVYg1KGSjeYO= NWPiTo1VTE2VTx?= NIL3TW5KSzVyPUSuN|Yh|ryP
GXF251L MnPWR5l1d3SxeHnjJGF{e2G7 MlXEOEBl[Xm| Ml;LSG1UVw>? NUn4SFd3UUN3ME2yMlI2KM7:TR?=
NCI-H23 NFz1bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ico44OiCq M1\kXWROW09? MnjPTWM2OD1{LkK3JO69VQ>?
HCT116 M3qyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r2clczKGh? NVG5WGlRTE2VTx?= MVXJR|UxRTJwMzFOwG0>
MCF7 M3:xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPGNpU4OiCq NFT0UmFFVVOR M3T2ZmlEPTB;Mj61O{DPxE1?
NCI-H460 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LvUlczKGh? MkXlSG1UVw>? MoO1TWM2OD16Lkm5JO69VQ>?
DLD1 NXvDeZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjlRVVLPzJiaB?= MkjySG1UVw>? MoP5TWM2OD12Lk[g{txO
NCI-H661 NGLmTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:zO3NOPzJiaB?= NVXXOHgzTE2VTx?= Mn3DTWM2OD15Lkig{txO
A549 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrENWxnPzJiaB?= Mn;xSG1UVw>? M1PqXmlEPTB;OD6yJO69VQ>?
U937 M1rzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp M33ZTWROW09? M3Lp[2lEPTB;MUKuNkDPxE1?
HEK293 MoXpSpVv[3Srb36gRZN{[Xl? M{LUcVExyqEQvF2= NFfvRWxFVVOR NITaSFZKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=>
HUVEC Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\VTJoxNjF3wrFOwG0> M2CxeFczKGh? MlnLSG1UVw>? Mk\1TY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN
HUVEC NF7qXppHfW6ldHnvckBCe3OjeR?= MUOxOeKh|ryP MknDO|IhcA>? M1myN2ROW09? MnLMTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0>
Plasmodium falciparum NFn0dXRHfW6ldHnvckBCe3OjeR?= M1T6Z|ExyqEQvF2= NXL1dIdEOTVibXnu NXfUb2YzTE2VTx?= NFPJ[JJKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1?
PC3 NUnmXY9{TnWwY4Tpc44hSXO|YYm= MWiwMlEh|ryP MUm1JIg> M3K2TmROW09? M2LGSWlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=
DU145 NVHnbFJFTnWwY4Tpc44hSXO|YYm= NFjaeZMxNjFizszN M2q0VFUhcA>? MVTEUXNQ MkTrTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=
PC3 MX;LbY5ie2ViQYPzZZk> MVqwMlEh|ryP MW[1JIg> M1q4[mROW09? NXrGb5g6UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>
DU145 NWPpfmlwU2mwYYPlJGF{e2G7 MnHiNE4yKM7:TR?= MkjMOUBp M2LzZWROW09? NEfiW4hKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0>
PC3 M3HvWGtqdmG|ZTDBd5NigQ>? NFTxfWIxNjFizszN Mn\YOUBp NUTm[YJRTE2VTx?= MW\Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>
DU145 MWDLbY5ie2ViQYPzZZk> NYXGUll{OC5zIN88US=> MkjlOUBp NG\UUotFVVOR MlTsTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?
Huh7 MkLwRY51cX[rcnHsJGF{e2G7 M4Tj[lIvPSEQvF2= NHHKWGg1KGSjeYO= MXfEUXNQ MU\Jcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?
C6/36 MYjBcpRqfmm{YXygRZN{[Xl? MYmyMlUh|ryP NH;G[WI1KGSjeYO= NV3v[XdqTE2VTx?= M2Pnd2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?
U937 M3PQ[mZ2dmO2aX;uJGF{e2G7 M{jTZVEh|ryP Mk\SNUBp MnX0SG1UVw>? MW\S[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>?
U937 NIfkeplHfW6ldHnvckBCe3OjeR?= MUKxJO69VQ>? MlHWNUBp MVXEUXNQ NGT4d3pT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>?
murine mast cell NVPlNWQzTnWwY4Tpc44hSXO|YYm= NW\3eoo{OSEQvF2= M1K0WVI1KGh? MV3EUXNQ NWT1[mhzUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2=
BV-173 M1GxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tb2lEPTB;MD6wNFAxODBzMEmg{txO
K-562 NX\Oe2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMECwNFAxOjZ4IN88US=>
BL-70 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;pTWM2OD1yLkCwNFAxODh{MjFOwG0>
EM-2 NI\rO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3rcWZKSzVyPUCuNFAxODBzMEig{txO
LAMA-84 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULs[3FRUUN3ME2wMlAxODByM{KxJO69VQ>?
MEG-01 NF:4S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqxTWM2OD1yLkCwNFAxQThizszN
EoL-1-cell NIfVfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD1yLkCwNFAyOzFizszN
CTV-1 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMECwNFQxPCEQvF2=
TE-15 NE[2bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\YSVltUUN3ME2wMlAxPTh7IN88US=>
NOS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPmUnhGUUN3ME2wMlAxPjF|IN88US=>
D-336MG NHG0XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTFT5ZCUUN3ME2wMlAxPjNizszN
LB1047-RCC NYO3UW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEC5PFkh|ryP
LB996-RCC M4P2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vFS2lEPTB;MD6wNFk6OSEQvF2=
SW982 NULCZpJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqeZZ6UUN3ME2wMlAyOTF3IN88US=>
TK10 M4HYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEGxO|Qh|ryP
A704 M2WxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnDTWM2OD1yLkCxOFkyKM7:TR?=
TE-8 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD1yLkCxOVc3KM7:TR?=
DOHH-2 NUXvRVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvEeGtKSzVyPUCuNFE4OTlizszN
HOP-62 NVHvfZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnZeIttUUN3ME2wMlAyQDN2IN88US=>
TE-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfrTWM2OD1yLkCxPFYyKM7:TR?=
KGN NHrxVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDiTWM2OD1yLkCxPVQzKM7:TR?=
NCI-H1648 NFj4WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPuTWM2OD1yLkCyNFEyKM7:TR?=
OS-RC-2 NH61WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEKwN{DPxE1?
GB-1 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[1RmlEPTB;MD6wNlE2PyEQvF2=
RXF393 NX3LVJk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XIRWlEPTB;MD6wNlM2PyEQvF2=
LC-2-ad MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu4TWM2OD1yLkCyOVg3KM7:TR?=
KS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TJdGlEPTB;MD6wNlc{KM7:TR?=
ETK-1 M3roTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnKUWhJUUN3ME2wMlAzQDN{IN88US=>
SW954 NGTJNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrW[HNKSzVyPUCuNFI6OjdizszN
Becker Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojKTWM2OD1yLkCzNFA{KM7:TR?=
MZ1-PC NVfpbop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEOxNVkh|ryP
ES6 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fKZmlEPTB;MD6wN|E6OyEQvF2=
KURAMOCHI NGLldm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHLNnJZUUN3ME2wMlA{PDh5IN88US=>
CGTH-W-1 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrjO2RKSzVyPUCuNFM2PDhizszN
VA-ES-BJ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEO5NFIh|ryP
LXF-289 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfuSZNrUUN3ME2wMlA{QTV4IN88US=>
MPP-89 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMESwOFkh|ryP
SW872 NH;ibYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TONGlEPTB;MD6wOFE3OSEQvF2=
SNB75 M2DJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fuTWlEPTB;MD6wOFQ{PSEQvF2=
PSN1 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMES0O|Qh|ryP
LB831-BLC NVrqUGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17tT2lEPTB;MD6wOFYxQSEQvF2=
MFH-ino MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HvOmlEPTB;MD6wOFczPCEQvF2=
TGBC24TKB M2jKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jEN2lEPTB;MD6wOFc3OSEQvF2=
A388 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnnR5ZKSzVyPUCuNFUxQTVizszN
BB30-HNC NW\xRWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEW0N|ch|ryP
GI-ME-N MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq5TWM2OD1yLkC2NVE5KM7:TR?=
TGBC1TKB M{PJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3oSVNNUUN3ME2wMlA3OTZ2IN88US=>
TE-10 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCzN4NKSzVyPUCuNFY{PTdizszN
A498 M4jlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPk[Vg5UUN3ME2wMlA4Ojh2IN88US=>
TE-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fLUWlEPTB;MD6wO|g2QCEQvF2=
BB65-RCC NUjCVGRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3J[JFuUUN3ME2wMlA5OjJ5IN88US=>
C2BBe1 NGDqbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fY[2lEPTB;MD6wPFMxQCEQvF2=
NCI-H747 M{G1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP3bGpwUUN3ME2wMlA5OzZ{IN88US=>
IST-MES1 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnRbZZKSzVyPUCuNFg2PTJizszN
KALS-1 M3fyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEm0PUDPxE1?
GCIY NIfZ[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDZcY44UUN3ME2wMlA6PjV4IN88US=>
RL95-2 NV;MZ4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfETWM2OD1yLkGwN|gh|ryP
TE-1 NV;0XZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj1NIxKSzVyPUCuNVA2PCEQvF2=
NCI-H1355 M4rjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnORoRxUUN3ME2wMlEyODJ6IN88US=>
SW962 M3THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUGyPVIh|ryP
KLE M1;Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMUGzNVch|ryP
MC116 NYfSd3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMUG0NUDPxE1?
NMC-G1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPFd20yUUN3ME2wMlEyPjB4IN88US=>
KU812 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H5eGlEPTB;MD6xNVg5OyEQvF2=
COLO-829 NVTRU2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn5T|RKSzVyPUCuNVIzOTNizszN
NTERA-S-cl-D1 NVL6UWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1yLkGyNlg{KM7:TR?=
IST-MEL1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHyTWM2OD1yLkGzOFUh|ryP
MLMA MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjsNpV2UUN3ME2wMlE1ODN{IN88US=>
LS-123 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fjTmlEPTB;MD6xOFA3PCEQvF2=
LB2518-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUSxOlIh|ryP
NB69 NF62eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXpVVJ{UUN3ME2wMlE1PDN4IN88US=>
8-MG-BA MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntbGE6UUN3ME2wMlE2PDV6IN88US=>
K5 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMU[0PFkh|ryP
KINGS-1 NEfmdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fjSWlEPTB;MD6xOlY3PiEQvF2=
SF268 M4Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnQPWdJUUN3ME2wMlE4PDB2IN88US=>
PF-382 NESw[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PSVmlEPTB;MD6xO|Y4QCEQvF2=
SH-4 NUPNOZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMUi0NVMh|ryP
NALM-6 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUmyPVUh|ryP
CP66-MEL M3zxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn3SoZKSzVyPUCuNVk2OzFizszN
697 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUm5PFch|ryP
CP67-MEL M{mzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMkC0PFgh|ryP
DSH1 M3TGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jHcGlEPTB;MD6yOFAxOSEQvF2=
HCE-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nkN2lEPTB;MD6yOlQ{QSEQvF2=
MZ2-MEL NF\C[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMki1N|ch|ryP
BL-41 NXzuVIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMkmxNlMh|ryP
HUTU-80 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwM{G0NkDPxE1?
LOXIMVI M{PmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwM{G1NFMh|ryP
no-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvQTWM2OD1yLkOxPVMyKM7:TR?=
KARPAS-422 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M375W2lEPTB;MD6zN|k6PyEQvF2=
SW684 M4\neWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DrW2lEPTB;MD6zOFk5KM7:TR?=
SF126 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrI[pQ{UUN3ME2wMlM2PDFizszN
D-263MG M{Dlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH5dpFuUUN3ME2wMlM3OjJ2IN88US=>
OVCAR-4 M{jKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OwcWlEPTB;MD6zO|Q{OyEQvF2=
BB49-HNC MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2TWM2OD1yLkO4OVk6KM7:TR?=
ONS-76 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO3TWM2OD1yLkSyPVUyKM7:TR?=
MZ7-mel MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1yLkS3PVEyKM7:TR?=
RCC10RGB M{G4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPod3hKSzVyPUCuOFkyOSEQvF2=
BOKU MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M370OWlEPTB;MD60PVE{OyEQvF2=
no-11 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7WNIVKSzVyPUCuOVAzOjhizszN
IST-SL2 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwNUCzNFIh|ryP
RKO Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwNUK5OlYh|ryP
HT-144 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj5eWVtUUN3ME2wMlU{PjB7IN88US=>
NCI-H446 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXOTYlSUUN3ME2wMlYzPzZizszN
QIMR-WIL MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G2UWlEPTB;MD63NFYzQSEQvF2=
MHH-PREB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfkfpdKSzVyPUCuO|Q1PjlizszN
EW-16 NXPDO|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfxW4pKSzVyPUCuO|YyPzhizszN
EW-24 NYmxOm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wTWM2OD1yLke4NVY2KM7:TR?=
LB373-MEL-D NGD5SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XvZWlEPTB;MD64NlUxQCEQvF2=
TE-9 NITRd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37yemlEPTB;MD64O|U{OiEQvF2=
A3-KAW MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nSe2lEPTB;MD65PFQ2OiEQvF2=
A101D MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;xcWlEPTB;MT6wN|A1OyEQvF2=
OCUB-M Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7aTWM2OD1zLkC0OFEzKM7:TR?=
ES4 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4OWlEPTB;MT6wOVE1PSEQvF2=
TE-6 NFG4PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLUTWM2OD1zLkKxNlI3KM7:TR?=
D-502MG Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\ZTWM2OD1zLkKzN|c3KM7:TR?=
KNS-42 NGrLeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK4PIhKSzVyPUGuNlQ1OTJizszN
SNU-C2B MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwM{C1PFkh|ryP
NCI-H1838 M1K3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDMTWM2OD1zLkOwO|M{KM7:TR?=
NKM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyydXRKSzVyPUGuN|A5PTlizszN
GI-1 M3jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvxTWM2OD1zLkO2NlIh|ryP
NB5 NHfpT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHriOFJKSzVyPUGuN|k5OjdizszN
CAS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvDTWM2OD1zLkSwPVkzKM7:TR?=
HCE-T NUDsSGV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfjOGNKSzVyPUGuOVY4OTRizszN
SBC-1 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwNUe5PFQh|ryP
JiyoyeP-2003 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaOopWUUN3ME2xMlc{PDZ4IN88US=>
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfsSoNKSzVyPUGuO|kyOzlizszN
CAN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHZTWM2OD1zLkiyNlUzKM7:TR?=
SK-UT-1 M3XzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyxd41nUUN3ME2yMlE3Pjl|IN88US=>
JVM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVfnkzUUN3ME2yMlM3Ojh2IN88US=>
LB771-HNC NXrX[W82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\SO5pKSzVyPUKuOVc2PTFizszN
NCCIT NUnMVm5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwOE[2NVYh|ryP
NCI-H2126 NWLzflFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHjTWM2OD1{Lki3OVUzKM7:TR?=
Calu-6 NV;6NFJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjvbFhKSzVyPUOuNFU4PDFizszN
SK-LMS-1 NHP0UolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwMUG4PFYh|ryP
ARH-77 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwNE[5NVUh|ryP
NB17 NEHXW4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lTWM2OD1|Lk[zPFQ4KM7:TR?=
A253 M2niUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwN{OyOFYh|ryP
OPM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfoU|JxUUN3ME20MlI4Pjh3IN88US=>
MV-4-11 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jWN2lEPTB;ND6zOlQ2PCEQvF2=
SR NYr1bnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRwNEm5OVQh|ryP
KG-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fHZ2lEPTB;ND62NFg1PSEQvF2=
OCI-AML2 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml33TWM2OD13Lki2NVU1KM7:TR?=
D-247MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTZwMUK1NVkh|ryP
DJM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzMTm1PUUN3ME22MlQ5PTV6IN88US=>
RPMI-6666 NFqwbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG3RYNKSzVyPUeuNlcxPjdizszN
KARPAS-45 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorhTWM2OD15LkWxOlcyKM7:TR?=
LP-1 M3XxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4R2lEPTB;Nz61OFc5OiEQvF2=
RS4-11 NXXz[ZJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy2UW1KSzVyPUeuOlU4QDdizszN
DU-4475 NFrYZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorUTWM2OD16LkKxOlUzKM7:TR?=
MONO-MAC-6 NVTGTlV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;W[VhKSzVyPUiuNlcxPjZizszN
NCI-SNU-16 NHnid29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xm[GlEPTB;OD61OlEzQCEQvF2=
SJSA-1 M4j2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRThwN{K4NFUh|ryP
MMAC-SF M4TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HFNGlEPTB;OD63PVMxPyEQvF2=
SK-NEP-1 NGnQRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRThwOEmxOVUh|ryP
J-RT3-T3-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTkTWM2OD16Lkm2OVI6KM7:TR?=
SKM-1 NXHUVJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTlwMEG3N|Qh|ryP
LB2241-RCC M2C4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1fW4zUUN3ME25MlAzODF{IN88US=>
SIG-M5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHHfFNHUUN3ME25MlAzPDl|IN88US=>
EVSA-T M1jqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnUN2txUUN3ME25MlI4Pzl|IN88US=>
GT3TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTlwM{W1OFYh|ryP
NB6 NHHNOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwOUKyOVkh|ryP
EHEB NEDZdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3na[mlEPTB;MUCuNFY2PiEQvF2=
HEL M3K4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:3Ro81UUN3ME2xNE41Pzd4IN88US=>
ALL-PO M2\hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD1zMD63PVM5KM7:TR?=
TGW NYHJRWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFzLkK4Nlgh|ryP
BC-3 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu3PFZKSzVyPUGyMlEyOzhizszN
IA-LM NXzuR3l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnZTWM2OD1zMj60OFQ2KM7:TR?=
UACC-257 M{HTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknHTWM2OD1zMj65NVk5KM7:TR?=
KP-N-YS NFO1PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD1zMj65Nlg{KM7:TR?=
Raji NU\4W2x6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D6OWlEPTB;MUOuO|Q6PyEQvF2=
SF539 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz3OIRKSzVyPUGzMlg2PTdizszN
DMS-153 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF2LkCwNlgh|ryP
L-540 Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF3LkC2O|Ih|ryP
MN-60 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHOTWM2OD1zNT6xPVc6KM7:TR?=
RPMI-8866 NHLqVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInWTIhKSzVyPUG3MlQ1PTRizszN
NCI-H510A M1fnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQT3N6UUN3ME2xPU4{QTd|IN88US=>
NB13 M1nPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXlbnZKSzVyPUG5MlQ5PzdizszN
HAL-01 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF7Lke1OFMh|ryP
NCI-H720 NWXlZoY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJyLkK3N|Mh|ryP
REH NE\OU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi5Xlc5UUN3ME2yNE43OzV5IN88US=>
KNS-81-FD NXfX[|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD1{Mz6xOFYh|ryP
HC-1 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjmTG5wUUN3ME2yOE42PTVzIN88US=>
NCI-H2141 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTWXoFKSzVyPUK0Mlc4PTRizszN
MOLT-4 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4Lk[3OVMh|ryP
OMC-1 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;xeGlEPTB;MkeuNVQzOiEQvF2=
LC-1F MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPMcYxmUUN3ME2yO{4{OjR3IN88US=>
NCI-H1304 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DTcWlEPTB;MkiuNVYzQCEQvF2=
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjocJdKSzVyPUK4MlY2OSEQvF2=
NCI-H64 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvmTWM2OD1{OT62NlU{KM7:TR?=
MOLT-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfGTWM2OD1{OT62NlkzKM7:TR?=
U-87-MG NUX4O5VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD4UFNQUUN3ME2zNE44PjZizszN
GAK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyTWM2OD1|MT6yOlg3KM7:TR?=
ES8 NYTjdGFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XT[mlEPTB;M{KuNVI2OiEQvF2=
HCC1599 M2SySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKySmpKSzVyPUOyMlM{OjVizszN
EB-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfITWM2OD1|ND6zNVE4KM7:TR?=
HCC1187 NYXRWWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\JeXFKSzVyPUO1MlgxPTJizszN
SK-PN-DW NVrOcI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nY[WlEPTB;M{[uNVk1OyEQvF2=
JVM-3 NWfSSGduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmUmlEPTB;M{euNlM{QCEQvF2=
HCC2157 NEjlR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrtcY1KSzVyPUO3Mlk6PDZizszN
A4-Fuk MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{myXWlEPTB;M{iuNVAxQSEQvF2=
COR-L279 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRyLkK4OVEh|ryP
DEL M1;Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILVNXlKSzVyPUSxMlkxQDZizszN
NCI-H1395 M1zpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jMTmlEPTB;NEKuNFE3OyEQvF2=
MHH-NB-11 NWTMcVFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T1dGlEPTB;NEOuNFgyQCEQvF2=
NCI-H2107 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrmTWM2OD12Mz60PFQ3KM7:TR?=
NEC8 NIfWOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTR2LkOzOkDPxE1?
COLO-684 NGOwdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnQdWhzUUN3ME20Ok4zOjV6IN88US=>
LS-411N MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TkR2lEPTB;NEiuOFc1QCEQvF2=

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

カスタマーフィードバック (10)


Click to enlarge
Rating
Source Cell Res, 2011, 21, 1080-1087. Dasatinib purchased from Selleck
Method Microangiography
Cell Lines embryos
Concentrations 30 μM
Incubation Time
Results MEK1/2 may cooperate with VEGFR to regulate blood vessel lumen diameter. We examined this hypothesis by combining VEGFR inhibitor Sunitinib and MEK1/2 inhibitor U0126. Indeed, U0126 (10 µM) combined with Sunitinib (20 µM) resulted in a reduction of vessel lumen size (Figure F), whereas individually they did not. Combined treatment of another MAP kinase signaling pathway inhibitor Dasatinib (20 µM) with Sunitinib (20 µM) produced a similar phenotype as PP1, whereas each individual inhibitor did not result in any vessel shrinkage even at much higher concentrations ( Figure C).Since there are three major VEGF receptors, it is desirable to determine which receptor is involved in combinatory action with MEK1/2. To address this issue, additional highly selective VEGFR inhibitors PTK787 and ZM323881 were tested. Both of these inhibitors (PTK787 or ZM323881), when individually combined with Dasatinib or U0126, induced a reduction of vessel lumen size (Figure D, E, G, and H).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Assessment of cell viability and apoptosis
Cell Lines B-CLL patient leukemic cells
Concentrations 2-10 μM
Incubation Time 48 h
Results The Dasatinib+Nutlin-3 combination promotes synergistic cytotoxicity in primary CLL cells as well as in p53 wild-type and p53 deleted/ mutated leukemic cell lines.

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Western blot
Cell Lines Leukemic cell lines
Concentrations 10 μM
Incubation Time 24 h
Results Dasatinib marginally affected both the basal levels of p53 and the accumulation of p53 induced by Nutlin-3 in the p53 wild -type cells (Fig. A).Interestingly, however, levels of both MDM2 and p21 proteins, 2 of the best characterized transcriptional targets of p53, weres significantly (P < 0.05) decreased in cells treated with Dasatinib+ Nutlin-3 with respect to cells treated with Nutlin-3 alone (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Phospho-kinase array analysis
Cell Lines EHEB cell lines/BJAB cell lines
Concentrations 10 μM
Incubation Time 16 h
Results Although Nutlin-3 had no effects on these pathways, Dasatinib alone as well as Dasatinib+Nutlin-3 markedly inhibited the basal phosphorylation of ERK1/2, p38/MAPK, and Akt . Of interest, the combination of Dasatinib+Nutlin-3 selectively enhanced (P < 0.05) the inhibition of Akt phosphorylation with respect to Dasatinib alone, as validated by Western blot analysis.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method MTT assay
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 1-15 μM
Incubation Time 24-72 h
Results Dasatinib and other TKI decreased the viability of the two myeloid cell lines in a dose- and time-dependent manner. Nevertheless, the anti-leukemic efficacy of Dasatinib and other TKI varied considerably in both cell lines.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method Evaluation of differentiation
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 5 μM
Incubation Time
Results In a first series of experiments, we assessed four signs of morphological differentiation, May-Gruenwald-Giemsa staining of MOLM-13 cells demonstrated that dasatinib induced a dose-dependent decrease in cytoplasmic basophilia and in the nucleo-cytoplasmic ratio. Dasatinib also led to the appearance of dented nuclei and cytoplasmic granulation( Fig.A and B).In HL-60 cells,dasatinib(5 μM) once more exhibited the highest differentiation-inducing capacity. Thus dasatinib diminished basophilia of the cytoplasm concomitantly with the nucleo-cytoplasmic ratio, and induced the appearance of nuclear lobulation and cytoplasmic granules(Fig. G). Next, we determined the degree of CD11b expression, a marker indicating myeloid differentiation, in TKI-treated MOLM-13 dasatinib exhibited the most pronounced capacity to increase CD11b surface expression( Fig. C and D).To corroborate the TKI-driven differentiation, we quantified the enzymatic activity of alkaline phosphatase by means of the NBT-reduction assay after an incubation period of 6 days in MOLM-13 cells.,Once again, the NBT-reductive activity was highest in cells treated with dasatinib, which was as active as the positive control, ATRA( Fig. E and F)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Assessment of cell viability
Cell Lines leukemic cells
Concentrations 10 μM
Incubation Time 24/48 h
Results Dasatinib dose-dependently reduced cell viability in all leukemic cell lines, with variable efficacy irrespect ively of the p53 status. In particular, when used at 10 μM, Dasatinib induced a progressive decrease of the total number of viable cells ranging from approximately 30% (JVM-2 and MEC-2) to 50% (EHEB and BJAB) after 48 h of treat ment (Fig.a). In order to investigate whet her the decreased leukemic cell viability was mainly due to either cytotoxic or cytostatic activity, we have analyzed the effects of Dasatinib on apoptosis,As shown in Fig. b, exposure to Dasatinib induced a significant (p < 0.05) increase of apoptosis in all leukemic cell lines, as evaluated by Annexin-V/PI staining at 48 h of treatment.

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method phospho-kinase array analysis
Cell Lines EHEB (p53wt) cell lines, BJAB (p53mut) B cell lines
Concentrations
Incubation Time 24 h
Results As shown in Fig. a , the most evident effects of Dasatinib in both cell models were represented by a significant down-regulation of the phosphorylation levels of p38 MAPK, ERK1/2 and CREB. In addition, densitometric analysis of the phospho-kinase array demonstrated that Dasatinib also inhibited the phosphorylation levels of several STAT family members (STAT1, STAT2, STAT3, STAT5a/b and STAT6), the most evident effect in both p53 wild-type (EHEB) and p53 mutated (BJAB) cell lines being on STAT2, STAT3 and STAT6 (Fig. b)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Western blot
Cell Lines p53wild-type(EHEB, JVM-2) cell lines, p53mutated(MEC-2, BJAB) cell lines
Concentrations 10 μM
Incubation Time 24 h
Results "Upon exposure to Dasatinib, a decrease of phosphorylated proteins was confirmed by Western blot analys is in all cell lines investigated without significant differences between p53wild-type and p53mutated cell lines.

Click to enlarge
Rating
Source Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck
Method Cell vability assays
Cell Lines A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2, HepG2 cell lines
Concentrations 0.001-1000 nM
Incubation Time 24/96 h
Results

文献中の引用 (59)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2nM and 6 nM, respectively.

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • BAY 87-2243

    BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ